Protected:
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
In fiscal 2015, top selling drug in ophthalmic space in Japan was Eylea (62.7% increase vs. 2014) and it jumped from second place to surpass the former leader Lucentis (19.1% decrease vs. 2014). Still, Lucentis is increasing sales generator for Novartis Japan 3-rd year in a row. Lucentis Sales in […]